Physician profile
Daniel Gallares
NPI 1245689488
$5,468.96
in general payments reported to CMS, 2019-2025
25 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,694 · 2020: $2,178 · 2021: $738 · 2022: $249 · 2023: $129 · 2024: $237 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $812.51 | 2019-2021 | |
| Gilead Sciences, INC. | $579.38 | 2021-2025 | Yeztugo, Biktarvy, Descovy |
| Abbvie INC. | $572.07 | 2019-2022 | |
| Allergan, INC. | $508.71 | 2019-2020 | |
| Lilly USA, LLC | $417.11 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.95 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $359.47 | 2019-2022 | |
| Pfizer INC. | $279.18 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $266.46 | 2019-2020 | |
| Amgen INC. | $252.85 | 2020-2021 | |
| Horizon Therapeutics Plc | $211.70 | 2020-2023 | Krystexxa |
| Amarin Pharma, INC. | $147.64 | 2020-2021 | |
| Novo Nordisk INC | $134.68 | 2020-2021 | |
| Viiv Healthcare Company | $106.19 | 2022 | |
| Glaxosmithkline, LLC. | $82.03 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $63.78 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $63.41 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $50.17 | 2021 | |
| Ironwood Pharmaceuticals, INC | $47.15 | 2020 | |
| Vifor Pharma, INC. | $43.93 | 2020 | |
| Insmed, INC. | $23.52 | 2020 | |
| Novartis Pharmaceuticals Corporation | $23.15 | 2021 | |
| Merck Sharp & Dohme LLC | $19.51 | 2020 | |
| Radius Health, INC. | $16.77 | 2020 | |
| Leo Pharma INC. | $16.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gallares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.